Older AdultsSubstance Use Disorders (SUD)Public Health, Prevention & Behaviour ChangeLSDMescalinePsilocybin

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study

In a nationally representative US sample (NSDUH 2015–2019), lifetime peyote use was associated with a greater than 50% reduction in the odds of cocaine use disorder (adjusted OR 0.47) and lowered odds on seven of 11 CUD criteria, whereas psilocybin, LSD and mescaline showed no protective association or were linked to increased odds. The authors recommend studies to examine demographic, personality and contextual confounds and longitudinal research to determine causality and therapeutic potential.

Authors

  • George Jones
  • Matthew Nock

Published

Scientific Reports
individual Study

Abstract

Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms of addiction. Thus, the goal of this study is to assess protective associations that lifetime use of classic psychedelics may share with CUD within a nationally representative sample of the U.S. We used data from The National Survey on Drug Use and Health (NSDUH) (2015–2019) and conducted survey-weighted multivariable logistic regression to test whether each of four classic psychedelics (peyote, mescaline, psilocybin, LSD) conferred lowered odds of CUD and its related 11 sub-criteria. Participants were 214,505 adults in the NSDUH (2015–2019) aged 18 and older. Peyote conferred lowered odds of CUD, reducing the odds of CUD by over 50% (aOR: 0.47). All other substances (including other classic psychedelics) either shared no association to CUD or conferred increased odds of CUD. Furthermore, sensitivity analyses revealed peyote to confer sharply lowered odds of the majority (seven of 11) of CUD criteria as well (aOR range: 0.26–0.47). Peyote use is associated with lowered odds of CUD. Future inquiries into third variable factors (i.e., demographic/personality profiles of individuals who use peyote, motivational/contextual factors surrounding peyote use) that may underlie our observed associations may reveal protective factors that can inform treatment development for CUD. Additionally, future longitudinal studies can shed further light on whether there is a temporal link between peyote use and lowered odds of CUD.

Available with Blossom Pro

Research Summary of 'Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study'

Introduction

Cocaine use disorder (CUD) is described as a substantial public‑health problem in the United States, associated with elevated morbidity and mortality and with limited effective pharmacological treatments. Earlier research has suggested that naturalistic use of classic psychedelics is associated with lower odds of some deleterious outcomes and that psychedelics may have promise in treating addictive disorders, but population‑level evidence specifically linking individual classic psychedelics to CUD has been limited and inconsistent. Jones and colleagues set out to test whether lifetime use of four commonly reported classic psychedelics — peyote, mescaline, psilocybin and LSD — is associated with reduced odds of past‑year CUD. Using a large, nationally representative survey dataset, the investigators aimed both to examine associations with overall past‑year CUD and to probe which of the 11 DSM‑IV criteria for CUD might show protective associations, should any substance emerge as significant in the main analysis.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (30)

Papers cited by this study that are also in Blossom

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

The association of psychedelic use and opioid use disorders among illicit users in the United States

Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)

121 cited
Cessation and reduction in alcohol consumption and misuse after psychedelic use

Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)

211 cited
Show all 30 references
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
The relationships of classic psychedelic use with criminal behavior in the United States adult population

Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)

Associations between lifetime classic psychedelic use and markers of physical health

Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)

65 cited
292 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)

204 cited
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)

28 cited
Associations between lifetime classic psychedelic use and cardiometabolic diseases

Simonsson, O., Osika, W., Carhart-Harris, R. L. et al. · Scientific Reports (2021)

Psychedelics, personality and political perspectives

Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)

164 cited
Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

Cited By (7)

Papers in Blossom that reference this study

Health-related behavioral changes following the use of psychedelics in naturalistic settings

Teixeira, P. J., Jain, R., Penn, A. D. et al. · Preventative Medicine Reports (2025)

1 cited
Psychedelic therapy in the treatment of addiction: the past, present and future

Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)

Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample

Hendricks, P. S., Simonsson, O. · Journal of Psychopharmacology (2022)

6 cited
23 cited
45 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.